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Abstract
Background: Trypanosome-derived lymphocyte triggering factor (TLTF) is a molecule released by African trypanosomes
that interacts with the host immune system, resulting in increased levels of IFN-c production.
Methodology/Principal findings: TLTF and anti-TLTF antibodies were assessed in sera and cerebrospinal fluid (CSF) from
patients infected with Trypanosoma brucei gambiense (T. b. gambiense) in an attempt to identify alternative markers for
diagnosis and stage determination of human African trypanosomiasis or sleeping sickness. Seventy-four serum and sixty-
one CSF samples from patients with parasitologically confirmed infection and known disease stage along with 13 sera and
CSF from uninfected controls were tested. In serum the levels of anti-TLTF antibodies were unrelated to the disease stage. In
contrast, levels of anti-TLTF antibodies in CSF were higher in intermediate/late stages than in early stage disease patients.
Specificity of the detected antibodies was assessed by inhibition of TLTF bioactivity as represented by its ability to induce
IFN-c production. Additionally, TLTF was detected in CSF from late stage patients by Western blotting with the anti-TLTF
specific monoclonal antibody MO3.
Conclusions/Significance: These findings suggest a new possibility for disease diagnosis with focus on involvement of the
CNS through detection of TLTF and anti-TLTF antibodies in the CSF.
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Introduction
African trypanosomes are major pathogens of humans and
livestock. The pathogen is transmitted by the bite of infected tsetse
flies (Glossina sp.) and multiplies extracellularly in the blood and
tissue fluids of the human host. Two subspecies of Trypanosoma
brucei (T. b. rhodesiense and T. b. gambiense) cause human African
trypanosomiasis (HAT, commonly called sleeping sickness). After
replicating at the tsetse fly bite site trypanosomes enter the
hemolymphatic system (early stage or stage 1) [1,2]. Without
treatment the parasites invade the central nervous system (CNS;
late stage or stage 2), a process that takes months-to-years with T.
b. gambiense (West and Central African HAT) or weeks-to-months
with T. b. rhodesiense (East African HAT). The parasites cause a
meningoencephalitis leading to progressive neurological involve-
ment with concomitant psychiatric disorders, fragmentation of the
circadian sleep-wake cycle and ultimately to death if untreated
[1,2,3]. Currently over 60 million people living in 36 sub-Saharan
countries are at risk of contracting the disease [4,5,6]. Due to
reinforced surveillance the number of new cases reported in 2009
had fallen below 10,000 for the first time in 50 years. In 2010 the
estimated number of new cases was thought to be approximately
7139. [7].
A key issue in the treatment of HAT is to distinguish stage 1
disease from stage 2 disease, as the drugs used for the
treatment of stage 2 need to cross the blood-brain barrier [8,9].
The most widely used drug is melarsoprol (developed in 1949),
which is effective for T. b. gambiense and T. b. rhodesiense HAT,
but unfortunately melarsoprol leads to severe and fatal
encephalitis in about 5–10% of recipients despite treatment
for this condition [10,3,1]. Where HAT is endemic accurate
staging is therefore critical, because while failure to treat CNS
involvement leads to death, inappropriate CNS treatment
unnecessarily exposes an early-stage patient to highly toxic and
life-threatening drugs. The diagnosis of HAT in the rural
clinical setting, where most patients reside, still largely relies on
the detection of parasitaemia by blood smear and/or CSF
microscopy [11,12].
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Experimental studies have revealed that T. b. brucei releases
trypanosome-derived lymphocyte triggering factor (TLTF), trig-
gering CD8+ T cells to secrete IFN-c in a non-antigen-specific
manner [13,14]. The action of TLTF is not host species restricted
since both rat and human mononuclear cells can be activated to
secrete IFN-c. TLTF is conserved within the Trypanozoon
subgenus, including the human infective T. b. gambiense and T. b.
rhodesiense [15], and both TLTF and anti-TLTF antibodies can be
detected in mice infected with T. b. brucei [16]. Considering TLTF
as a trypanosome-specific molecule we investigated its potential for
serodiagnostic purposes in HAT. We describe TLTF and anti-
TLTF antibody detection in paired serum and CSF of patients
with T. b. gambiense HAT.
Materials and Methods
Ethical statement
The study was approved by the National Ethical Committee of
the Ministry of Health of the Democratic Republic of Congo
(D.R.C.). HAT patients gave written informed consent before
enrolment. Children (,18 years) or patients with altered mental
status, a common condition in late stage HAT, were only included
after written informed consent from a parent or a guardian. All
patients had the option of withdrawing from the studies at any
time.
Patients
Seventy-four serum and sixty-one CSF samples were collected
from patients in the Democratic Republic of Congo. They were
obtained for routine diagnostic purposes from parasitologically
confirmed T. b. gambiense patients before treatment during sleeping
sickness control activities. White blood cell (WBC) counts and
presence of trypanosomes in CSF were assessed in the hospital of
Bwamanda for stage determination. Storage was at 220uC in the
D.R.C. and at 270uC in Europe. Patients did not undergo
systematic screening for co-infections.
Patients were classified according to WHO criteria. The upper
limit for normal and cut-off values for the haemolymphatic stage
has been set at 5 WBC/microliter [17]. Patients with values
between 5–20 WBC/microliter are considered in the intermediate
stage. A WBC count .20 WBC/microliter or the presence of
trypanosomes in the cerebrospinal fluid (CSF) indicates the
meningo-encephalitic stage. Twenty-five patients were in the
Early (E) stage, 25 patients in Intermediate (I) and 24 patients in
the Late (L) stage. Six control serum and 13 control CSF samples
originated from Swedish Multiple Sclerosis patients attending the
Neurology Clinic at Karolinska Hospital, Sweden.
TLTF preparations
Recombinant TLTF (rTLTF) was prepared as described
elsewhere [18]. Based on previous studies native TLTF (nTLTF)
was prepared as follows. Monomorphic trypanosomes T. b. brucei
AnTat 1.1 were harvested 6 days post-infection from rats by
DEAE chromatography [19,20]. A 106/ml trypanosome suspen-
sion was incubated with 100 U/ml rat IFN-c for 1 hour at 37uC.
The supernatant was clarified by centrifugation at 12,000 g for
5 min before ultracentrifugation using JumboSep 100 kDa cut-off
filtration devices (Pall Gelman). The concentrated supernatant was
loaded onto a MONO Q ion exchange column (Pharmacia) in
50 mM Tris pH 7 and eluted with the same buffer containing 1M
NaCl using an FPLC system (Pharmacia). Eluted peaks were
collected separately, run in 10% SDS PAGE gels and silver
stained. TLTF was stored at 4uC.
Anti-TLTF ELISA
An ELISA was used to detect antibodies against TLTF in
patient sera and CSF, respectively. Flat-bottom 96-well polysty-
rene plates (polysorp F96, Nunc, Glostrup, Denmark) were coated
with 100 ml 10 ng/ml rTLTF in bicarbonate buffer pH 9.6
overnight at room temperature (RT). Control wells were coated
with 100 ml of 10 ng/ml ovalbumin in bicarbonate buffer pH 9.6.
Wells were washed five times with 200 ml phosphate-buffered
saline (PBS) containing 0.05% Tween-20 (PBS-T) and saturated
with 100 ml 1% bovine serum albumin (BSA) in PBS for 1 h at
RT. After washing the plates with 200 ml PBS-T, specimens were
dispensed into TLTF and ovalbumin coated wells in 100 ml
amounts at a 1:100 dilution in PBS for CSF and 1:1000 dilution
for serum. These dilutions were selected after testing several other
dilutions. After 1 h incubation at 37uC and five washes with 200 ml
PBS-T, 100 ml of biotinylated goat anti-human IgG (Sigma, St
Louis, MO, USA) diluted 1:1,000 in PBS were added for 1 h at
37uC. One hundred ml of avidin-biotin-alkaline phosphatase
conjugate (ABC-AP; Vector Laboratory, Burlingame, USA)
diluted 1:100 in PBS were added for 45 min. Five consecutive
washings with PBS removed unbound ABC-AP, and 100 ml of
freshly prepared enzyme substrate solution was added per well.
Absorbance was measured at 405 nm in a Multiscan photometer
(mcc/340; Lab system, Helsinki, Finland). For each specimen, a
corrected optical density (O.D.) was calculated.
Western blot for anti-TLTF detection
To confirm the specificity of anti-TLTF antibodies 8 mg/well
nTLTF was run in non-denaturing, 10% SDS PAGE preparative
gels, transferred to nitrocellulose membranes (Amersham) for
1 hour at 100 V and blocked with 5% low fat milk in PBS-T for
1 h at RT. The membranes were placed into a 20-channel Mini-
PROTEAN II Multiscreen apparatus (Bio-Rad, Sollentuna,
Sweden) and the channels were filled for 1 h at RT with 400 ml
of a 1:100 dilution of CSF with 5% low fat milk in PBS-T as a
reagent blank. After three washes with 500 ml PBS-T the
membrane was removed and incubated with 5 ml mouse anti-
human IgG horseradish peroxidase (HRP) conjugate (Amersham
International, Uppsala, Sweden) diluted 1:1,000 in 5% low fat
milk/PBS-T for 1 h at RT. After washing three times with 50 ml
PBS-T, substrate and chromogen solution was added to visualize
bound IgG (ECL system, Amersham). As positive control, similar
blots were run with 400 ml of 5 mg/ml MO3/channel and
developed with rabbit anti-mouse IgG-peroxidase conjugate.
Negative controls consisted of the same blots without human
specimen and without MO3.
Inhibition of TLTF bioactivity by CSF in ELISPOT
The ELISPOT method described and adapted to mouse IFN-c
was used to detect inhibition of IFN-c production by single
secretory cells [21,22]. Naive DBA/1 mice spleens were dissected,
splenocytes purified and viable cells were diluted to 26106/ml in
RPMI. The assay was performed in nitrocellulose bottomed 96-
well microtiter plates (Multiscreen HA; Millipore, Bedford, UK)
using 15 mg/ml IFN-c specific mouse monoclonal antibody DB1
[23] and 200 ml/well (46105 cells) of the above prepared cell
suspension. Twenty ml of native TLTF (nTLTF) were added to
triplicate wells at a concentration of 8 mg/well, with none being
added to unstimulated wells. Patient and control CSF samples
were diluted 1:10 in PBS and pre-absorbed with of 8 mg/ml
nTLTF for 30 min at RT. Twenty ml volumes of pre-adsorbed
samples were added in triplicate to the wells. Con-A was used as
positive control and similarly preabsorbed with patients CSF to
examine the specificity of the anti-TLTF antibodies.
TLTF Detection in Serum and CSF
PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e79281
Cells were cultured for 24 h before sequential incubation with
polyclonal rabbit anti-rat IFN-c antibody, 1:1000 swine anti-
rabbit biotinylated antibody and colour development with
avidin-biotin-alkaline phosphatase conjugate (ABC-AP; Vector
Laboratory, Burlingame, USA) and 3-amino-9-ethycarbazole
and H2O2 [24]. The spots were counted in an automatic
counter (TransTec) and the mean value of the triplicates
calculated for each sample.
Detection of TLTF in the CSF by Western blotting
CSF samples were diluted 1:100 5% low fat milk in PBS-T
and 20 ml of the non- denatured samples was added to each
lane and run in 10% SDS PAGE gels to test the presence of
TLTF in the samples. CSF samples from two patients in each
stage were run in parallel with the controls, MO3 was diluted
at 5 mg/ml and analysis by Western blotting conducted as
before.
Figure 1. Anti-TLTF antibodies in sera and CSF determined by ELISA. (a). Concentrations obtained in anti-TLTF ELISA in serum samples of
early stage (E, n = 25), intermediate stage (I, n = 25) and late stage (L, n = 24) patients. Differences between E, I and L are not significant from each
other but are significant compared to the control (C) samples (p = 0.0002). (b). Concentrations of anti-TLTF in CSF samples of early stage (E, n = 20)
patients, intermediate stage (I, n = 21) and late stage (L, n = 20) patients. Note the significant difference between intermediate and early stage
(P = 0.0005) and between intermediate and late stage (P,0.05). The levels of TLTF in CSF are represented in (mg/ml). The horizontal hatched line marks
the diagnostic cut-off value (2 mg/ml).
doi:10.1371/journal.pone.0079281.g001
TLTF Detection in Serum and CSF
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Statistical analysis
The non-parametric Mann-Whitney test was used to evaluate
statistical differences.
Results
Anti-TLTF antibodies in sera and CSF determined by ELISA
Concentrations of anti-TLTF antibodies were obtained
in serum, CSF and control samples. The control sera
gave low absorbance levels. Anti-TLTF antibodies were
detected in the sera of all HAT patients. There was no
significant difference between the mean concentrations of
each HAT group but mean concentrations obtained for
each of these groups differed significantly (p = 0.0002)
from the mean concentration obtained with the control
sera (Fig. 1 A).
In CSF, anti-TLTF antibodies were only detectable in the
intermediate and the late stage groups with no significant
difference (p = 0.029) of the mean concentrations between
either of these groups. In the early stage group and the
control sera the mean concentrations obtained were signifi-
cantly lower (p,0.001) than in intermediate and late stage
CSF and were thus considered negative for anti-TLTF
antibodies (Fig. 1B).
TLTF is detectable in CSF of late stage sleeping sickness
patients
After running CSF samples using Western blotting and an anti-
TLTF monoclonal MO3 as primary antibody, a 185 kDa band
indicative for TLTF was only detected in samples from late stage
patient CSF (Figure 2 A).
Specificity of CSF anti-TLTF antibodies for native TLTF in
Western blots
To test the specificity of CSF anti-TLTF antibodies detected by
ELISA non-denaturing Western blotting was performed with
nTLTF and 4 CSF samples from each HAT group (Figure 2 B).
Under these conditions TLTF appears as a single band at 185 kDa
[3] and was apparent in all 4 samples in late stage patients and in
one intermediate stage patient sample. MO3 used as a positive
control detected the same 185 kDa molecular weight band (data
not included). A smaller MW band may be a breakdown product
of TLTF. No bands were revealed in samples from the other
stages.
Figure 2. Specificity of CSF anti-TLTF antibodies for native
TLTF in Western blot. (a). Immunoblots to detect the presence of
TLTF in CSF from HAT patients and controls. The anti-TLTF monoclonal
antibody MO3 was used as a detection antibody and the presence of
TLTF in the CSF samples was revealed as a band with a MW of
approximately 185 kDa. (b) Immunoblots using CSF samples from each
stage of the disease to detect the occurrence of anti-TLTF antibodies in
CSF. Native TLTF (nTLTF) was used as an antigen in these experiments
and revealed as a band with a molecular weight of approximately
185 kDa.
doi:10.1371/journal.pone.0079281.g002
Figure 3. Inhibition of nTLTF bioactivity by CSF of sleeping sickness patients. Effect of preabsorption of 8 mg native TLTF (nTLTF) by anti-
TLTF antibodies in CSF samples from 3 patients and controls. Inhibition of nTLTF activity is reflected by a decreased number of IFN-c secreting cells
compared to the effect of nTLTF alone (P,0.05). Note the absence of preabsorption effects by anti-TLTF antibodies in the CSF samples on Con-A
stimulated IFN-c production, suggesting the specificity of the anti-TLTF antibodies detected in the CSF from the 3 patients.
doi:10.1371/journal.pone.0079281.g003
TLTF Detection in Serum and CSF
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Inhibition of nTLTF bioactivity by CSF of sleeping
sickness patients
To further investigate the specificity of anti-TLTF antibodies
detectable in CSF by ELISA and Western blotting, inhibition of
TLTF bioactivity assay was assessed by ELISPOT (Figure 3). The
number of IFN-c secreting cells stimulated with TLTF was 56+/
218 (mean+/2SD) compared to those that did not receive TLTF
(mean 5+/21.2). The same stimulatory effect was observed when
TLTF was mixed with control CSF samples before being added to
the cells (mean 60+/238). The numbers of IFN-c secreting cells
that received pre-adsorbed CSF samples of HAT patients were
significantly lower than in the TLTF-stimulated control wells
(p,0.005) and were comparable to unstimulated cells. Con-A was
used as positive control and yielded significantly higher induction
of IFN-c compared to unstimulated cells (p,0005). This action of
ConA was not inhibited by anti-TLTF antibodies in the CSF.
Discussion
TLTF is a glycoprotein released by bloodstream form trypano-
somes from the Trypanozoon subgenus, resulting in CD8+ T
lymphocyte activation and production of IFN-c. Experimental
studies have demonstrated in vivo production of TLTF during
infection and generation of anti-TLTF antibodies, correlation of
parasite load with the ability of TLTF to stimulate CD8+ T cells,
and active production of TLTF by living parasites in response to
IFN-c [16,19]. A role for TLTF in HAT has not yet been
demonstrated. In this report we assessed the usefulness of TLTF
and anti-TLTF antibodies as a HAT biomarker, with focus on
measurement in CSF.
Anti-TLTF antibodies were detected using ELISA in the serum
of all HAT patients, the antibody levels being independent of
clinical stage of the disease. This indicates that TLTF is released
by T. b. gambiense bloodstream forms from early on in the infection
in sufficient amounts to induce a humoral immune response. In
the CSF samples antibodies were only detectable in HAT patients
with evidence of trypanosome invasion of the central nervous
system (I and L stages), suggesting TLTF release by intrathecally
resident parasites and subsequent intrathecal antibody production.
The specificity of the anti-TLTF antibodies in CSF was
confirmed through Western blotting using a selection of the
samples. Purified native TLTF recognized by the specific
monoclonal MO3 was revealed in the same way by the late stage
CSF samples and some intermediate stage samples, but not by the
early stage samples. Further specificity confirmation evident in the
ELISPOT indicates that the production of IFN-c by mouse
splenocytes induced by nTLTF is inhibited when nTLTF is first
incubated with CSF samples containing anti-TLTF antibodies, but
this was not the case when Con-A was used as a positive control.
Earlier attempts to detect TLTF in serum of HAT patients
using capture ELISA were unsuccessful. This can be explained by
the characteristically low parasitemia of T. b. gambiense in HAT
patients, presumably resulting in release of TLTF amounts that
remain below the detection limit of the assay. Alternatively, TLTF
might be present but in complex with antibodies or by its target
receptor (CD8) and thus unavailable for the capturing monoclonal
antibody in non-denaturing ELISA conditions.
While the detection of TLTF in CSF implicates a role for its action
within the CNS, the presence and inhibitory character of anti-TLTF
antibodies in serum and CSF indicates a humoral immune response
that might interfere with the infection course. In this respect it would
be interesting to study TLTF and anti-TLTF profiles in biological
samples of HAT patients infected with T. b. rhodesiense. HAT caused
by this parasite usually causes a much more fulminant disease with
high parasitemia leading to death within a few months, in contrast
with T. b. gambiense that causes a chronic disease with death occurring
after several months or some years [25].
We cannot entirely exclude that other infections than trypano-
somiasis might have had an impact on potential brain inflamma-
tion/complications that could subsequently affect clearance/
penetration of trypanosome-derived macromolecules. Co-infec-
tions in the African continent may be a common event, and their
immunological consequences have been reported in a number of
settings [26–31]. Thus the production of an immunomodulatory
substance by trypanosome parasites is not unique, as exemplified
by eicanosoids during intracellular bacterial infections [32] and
excretory-secretory filarial substances [33,34]. This is thus an issue
that would be worthy of further attention, as it is possible that the
synergistic immunomodulatory effects of co-infections impacts on
the type and severity of pathology of a given parasite infection.
In conclusion, this work demonstrates a possible role for TLTF
in T. b. gambiense HAT pathogenesis. In addition, the profiles
presented here of anti-TLTF antibodies in CSF of HAT patients
opens perspectives for the development of alternative tests for both
diagnosis and differentiation of early versus intermediate/late
stage infections. Further work will be required to determine the
biological meaning and other possible applications of anti-TLTF
antibodies in CSF.
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